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disease and inflammation, but it is more reliable than 
ferritin for evaluation of body iron status in patients 
on chronic dialysis.[9]
Neutrophil geletinase-associated lipocalin (NGAL) is 
a small 25 kDa glycoprotein, a member of lipocalin 
superfamily that released at the response of cellular 
stress such as inflammation and ischemia from different 
cells such as renal tubules, liver hepatocytes, endothelial, 
and smooth muscle cells.[10-16]
Now-a-days, serum NGAL uses as an acute kidney 
injury marker, but basically it is a bacteriostatic 
substance that released from secondary granules 
of neutrophils.[17,18] In addition, NGAL was studied 
as an iron regulatory glycoprotein and regulator 
of iron related gene.[19-23] Later investigations show 
NGAL causes anemia due to oxidative stresses. In 
experimental models, medullary and systemic NGAL 
causes erythropoiesis inhibition through induction 
of apoptosis and inhibition erythroid precursor 
INTRODUCTION
About 90 % of patients with end stage renal disease 
(ESRD) have anemia [1] and it is associated with 
higher risk of death.[2] It seems common cause of 
anemia in children with ESRD is erythropoietin 
(EPO) deficiency,[3] but in many situations it is 
hyporesponsive to EPO. Its causes are different such 
as iron deficiency anemia (IDA)[4] and inflammation.[5] 
Children on chronic dialysis often have IDA, because 
of multiple blood sampling, gastrointestinal bleeding, 
dietary restriction, and decreased intestinal absorption 
due to phosphate medication.[6] According to Kidney 
Disease Outcome Quality Initiative suggestion, 
transferrin saturation (TSAT) and ferritin are the first 
tools for evaluation of iron status in renal disease. 
TSAT <20, ferritin <200 are two cut-off points for 
IDA in patients on chronic dialysis.[7] There are some 
difficulties about these markers, first ferritin is an 
acute phase protein and is different in both sexes,[8] 
second TSAT also influences by malnutrition, chronic 
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differentiation.[24-28] NGAL also at the response of renal 
tubular cell injury, redirect systemic iron to proximal 
tubule cells of kidney.[21,29]
Another study was done former on adults on chronic 
hemodialysis (HD) that show relationship between 
IDA and serum NGAL.[30] However, on the basis of our 
knowledge, no study has yet performed about association 
between serum NGAL level and IDA in children on chronic 
dialysis.
The aim of current pilot study was to evaluate the 
association between serum NGAL and body iron status in 
children on chronic dialysis.
MATERIALS AND METHODS
Study design and participants
This correlation study was performed between May 2012 
and May 2013. We selected for current study children who 
received treatment for ESRD (either HD or peritoneal 
dialysis [PD]) for a minimum of 6 months and didn’t have 
exclusion criteria at all Isfahan dialysis centers.They were 
40 patients, including 23 persons on HD and 17 person 
dialyzed by PD. Exclusion criteria were the presence or a 
recent history of bleeding, malignancy, liver, thyroid or 
infectious disease, recent increase in leukocyte count or 
treatment with immunosuppressor drugs.
HD group were on regular treatment for dialysis, 3 times 
a week about 4 h/each session on standard bicarbonate 
dialysis. HD and PD patients matched for age and sex 
and duration of dialysis. All dialysis children were on 
recombinant EPO treatment for at least 6 mount, none 
of them received iron or RBC in past 2 mounts. They 
were normotensive without edema. Causes of ESRD in 
these children were hypoplasia/dysplasia (n = 22), reflux 
nephropathy (n = 8), drug reaction (n = 2), metabolic disease 
(n = 3), and unknown (n = 5).
Control group was selected of healthy children that referred 
to clinic for assessment of body iron status. This group was 
matched for age, sex with dialysis children. They were on 
regular diet without consumption supplementary iron 
drugs.
Procedures and variable assessment
Sampling was carried out at hospital dialysis unit for 
HD patients and at routine laboratory assessment for PD 
patients. Samples transferred on ice to laboratory unit 
and quickly freeze on –20°C. Fasting serum samples were 
obtained in the early morning for biochemical studies. 
These biochemical variables were Cr, urea, hemoglobin, 
hematocrit, leukocyte count, serum iron (SI), TSAT, ferritin, 
transferrin iron binding capacity (TIBC), albumin, alkaline 
phosphates, para thyroid hormone, high-sensitivity 
C-reactive protein (hsCRP), and NGAL. All biochemical 
blood samples were collected before mid-week dialysis 
session in HD group.
Markers that measured for assessment of body iron status 
were SI, TSAT, ferritin, TIBC.
SI, ferritin measured by radioimmunoassay.TIBC 
measured through spectrophotometry. TSAT calculated 
by this formula: . Serum CRP was obtained to 
demonstrate the presence of inflammation and measured 
by immunoturbidometry. Plasma NGAL level measured 
by researched enzyme-linked immunosorbent assay (LOT. 
NO. KIT EKO 853, BOSTER biological Technology Co., Ltd.; 
Wuhan, China). Minimum detection limit was 10 ng/mL and 
coefficient of variation was <5%.
Other measurements were performed by routine automated 
laboratory tests.
Iron deficiency was defined as TSAT <20% and used 
for subdivision of patients to two groups to assessment 
correlation between serum NGAL level and iron status in 
children on chronic dialysis.
Statistics analysis
Data presented as mean ± standard deviation. Data analysis 
was performed by SPSS version 16 (SPSS Inc., Chicago, IL, 
USA). Normality of variables was assessed by Kolmogorov–
Smirnov test.
Differences between groups were determined by unpaired 
t-test and level of significance was 0.05. Pearson correlation 
coefficient test was used to show relationship between 
serum NGAL and different data. Chi-square test used for 
nonnumerical variables.
RESULTS
Table 1 illustrates the main characteristics of this study In 
group, including both HD and PD patients the mean age 
was 9 ± 2. Mean serum NGAL level was 327.3 ± 29.8 ng/mL, 
which was significantly higher than healthy controls 
(P = 0.008).
Hematologic markers (Hb and Hct) and iron status markers 
(TSAT, SI) in this group was significantly higher than 
healthy controls (P < 0.001). Inflammatory markers (such as 
hsCRP and ferritin), urea and creatinine as expected were 
higher than healthy controls (P < 0.05). Serum NGAL level 
in this group had inverse correlation with TSAT (P = 0.04, 
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r = −0.22), SI (P = 0.04, r = −0.2), white blood cells (P = 0.045, 
r = −0.26), and serum ferritin (P = 0.006, r = −0.3). Serum 
NGAL level in HD group also had inverse correlation with 
TSAT (P = 0.038, r = −0.18), SI (P = 0.042, r = −0.21).
Correlation between serum NGAL level in PD group and 
iron status markers such as SI, TSAT, and ferritin was 
reverse, but not significant (P = 0.063, r = −0.34).
Iron balance in children on chronic dialysis
Children on chronic dialysis was subdivided to two groups 
on the basis on absence or presence of IDA according 
to TSAT <20 (low TSAT group) or TSAT >20 (high TSAT 
group), so 17 patients (45%) belonged to low TSAT group 
and 23 patients (55%) belonged to high TSAT group, 
surprisingly between low TSAT group only 8 person 
(50%) simultaneously presented serum ferritin level under 
200. Differences between low TSAT group and high TSAT 
group were summarized in Table 2. Serum NGAL in low 
TSAT group was significantly higher than high TSAT group 
(P = 0.04). SI (P < 0.001), TIBC (P = 0.04), TSAT (P < 0.001) 
were significantly higher in high TSAT group. Differences 
in Hb, Hct, and ferritin between these two groups were not 
significant. Creatinine and urea in high TSAT group was 
higher than low TSAT group, but not significant (P > 0.05).
Comparison between hemodialysis and peritoneal 
dialysis patients
Table 3 summarized results of comparison between HD 
and PD patients.
A total of 17 patients (41%) belonged to PD group and 23 
patients (49%) belonged to HD group. HD patients presented 
significantly higher TSAT (P = 0.048), SI (P = 0.047), NGAL 
(0.04), urea (P = 0.010), and ALP (P = 0.001) than PD patients. 
Differences between hemoglobin and hematocrit between 
PD and HD patients were not significant (P > 0.05). Urea 
was significantly higher in PD than HD patients (P = 0.010). 
Creatinine was higher in PD patients, but not significant 
(P = 0.34).
DISCUSSION
There are some points to discussion in our study.
First, serum NGAL level in children on chronic dialysis was 
higher than healthy controls. We expected this consequence 
because according to previous studies NGAL was known 
as an acute phase protein that released by injured tissue 
such as renal cells.[31] In renal disease serum NGAL known 
as a primary indicator of organ damage[32] and in patients 
with chronic kidney disease (CKD) increased serum and 
urine level of NGAL is correlated with residue of renal 
function.
Second, there was a significant reverse correlation between 
serum NGAL and SI, TSAT, and ferritin in our study, 
this consequence can illustrated on the basis of previous 
investigations such as in one study, NGAL level was 
measured in blood, liver, and spleen after experimental 
induction of different types of anemia such as blood 
loss (phlebotomy, anemia induced by bleeding), IDA 
(sideropenic anemia) and hemolytic anemia (after phenyl 







Gender (male/female) 19/21 11/9 0.61
Age (years) 9±2 9±5 0.898
Creatinine (mg/dL) 6.21±0.3 0.75±0.2 <0.001
Urea (mg/dL) 53.9±21 8.5±2 <0.001
Hemoglobin (g/dL) 8.8±2.04 12.5±1.11 <0.001
Hematocrit (%) 27.05±6.26 36.6±3.2 <0.001
ALP (IU/L) 455.31±289 — —
PTH (pg/dL) 141.4±156 — —
WBC (n×106) 7.269±3.55 6.31±2.1 0.06
Albumin (g/dL) 5.44±12.43 5.34±10.2 0.44
hsCRP (mg/L) 6.2±17 0.11±0.03 0.04
Serum iron (mcg/mL) 75.05±28 105±12.2 <0.001
TIBC (mg/dL) 225±83 402.1±53.2 0.01
TSAT (%) 26.07±12.6 34.8±6.69 0.006
NGAL (ng/mL) 327.38±29.8 142.7±78.7 0.008
Ferritin (ng/mL) 166.5±164.5 118.7±44.02 0.208
hsCRP = High-sensitivity C-reactive protein; ALP = Alkaline phosphatase; 
TSAT = Transferrin saturation; TIBC = Transferrin iron binding capacity; 
PTH = Para thyroid hormone; NGAL = Neutrophil geletinase-associated lipocalin; 
WBC = White blood cell
Table 2: Comparison between low TSAT group and high 
TSAT group in main clinical





Gender (male/female) 7/9 14/10 0.56
Age (years) 9±5.5 9.6±0.4 0.73
Creatinin (mg/dL) 6.49±2.6 0.04±0.44 0.564
Urea (mg/dL) 55.8±15 52.62±23 0.658
Hb (g/dL) 9.25±1.9 8.6±2.1 0.35
Hematocrit (%) 28.57±5.4 26.03±6.6 0.21
ALP (IU/L) 424.15±244 522.8±387 0.505
PTH 113.7±69 159.9±194 0.36
WBC (n×106) 7.51±3.69 7.10±3.53 0.72
Albumin (g/dL) 3.48±0.78 6.74±16 0.424
hsCRP (mg/dL) 10.36±23 3.43±10.2 0.214
Serum iron (mcg/mL) 54±15 88.7±27 <0.0 01
TIBC (mg/dl) 249.6±67 209.2±89 0.04
TSAT (%) 13.8±4.32 34.25±9.19 <0.001
Serum ferritin (ng/mL) 205.06±186 140.9±146 0.232
NGAL 371.3±314 261.4±267 0.04
hsCRP = High-sensitivity C-reactive protein; ALP = Alkaline phosphatase; 
TSAT = Transferrin saturation; TIBC = Transferrin iron binding capacity; 
PTH = Para thyroid hormone; NGAL = Neutrophil geletinase-associated lipocalin; 
WBC = White blood cell
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hydrazine injection). In three upper situations, NGAL 
significantly increased in multiple organs such as liver and 
in two former conditions SI was decreased.[31] In one animal 
model, NGAL was able to separate iron from transferrin 
and redirect it from liver and spleen to renal proximal 
tubules to induce proliferation of these cells and inhibit 
their apoptosis.[30] In this study, serum NGAL level in 
low TSAT group was significantly higher than high TSAT 
group. According to findings of our study and previous 
investigations, we found out that NGAL except its role 
in prevention of erythropoiesis has an important role in 
production of IDA in CKD, it seem that mechanism of this 
effect is complicated, but its function in separating iron 
from transferrin and redirects it to proximal renal tubules 
can plays an important role.
In addition, comparison between low TSAT group and 
serum ferritin level under 200 revealed that ferritin was 
not an ideal marker for diagnosis IDA in CKD. Therefore, 
serum NGAL can be a new marker for diagnosis of IDA 
in CKD that more investigations with more participants 
need in future.
Third, it is well-known that HD patients have severe 
anemia than PD patients even with EPO treatment but SI 
in HD patients was higher than PD patients as a result of 
recurrent blood transfusion.[33] In addition to PD patients 
have better renal residual function than HD patients,[33] 
therefore on the basis of our findings in this study, we 
can explain these findings. NGAL level was higher in HD 
patients because of severe anemia and lower renal residual 
function in these patients.
Limitations
There were some limitations in the current study. First, 
participants were not as high as can extend these findings 
to all children on chronic dialysis. Second, we didn’t correct 
IDA and then measure NGAL level to identify cause-and-
effect relationship between serum NGAL and IDA.
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